Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cobimetinib + venetoclax
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cobimetinib + venetoclax is an investigational oral combination therapy comprising cobimetinib, a selective MEK1/2 inhibitor, and venetoclax, a selective BCL2 inhibitor. The combination targets the MAPK/ERK pathway (via MEK1/2) and the mitochondrial apoptotic pathway (via BCL2), promoting cell death and inhibiting proliferation in cancer cells. Preclinical and early clinical studies have demonstrated anti-leukemia activity in acute myeloid leukemia (AML), including synergy in drug-resistant AML and relapsed/refractory multiple myeloma (RRMM). Cobimetinib is developed by Genentech/Roche and venetoclax by AbbVie/Genentech/Roche.
- Brand names
- Cotellic + Venclexta
- Other names
- cobimetinib and venetoclax
02
Targets
BCL-2 (BCL-2 family)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on cobimetinib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cobimetinib + venetoclax.